Last reviewed · How we verify

NCT07044973: Dual-TargetFUS

VIM+PTT MRgFUS for PD

Recruiting now NA Last updated 1 July 2025
What this trial tests

NA trial testing Transcranial focused ultrasound thalamotomy in Parkinson Disease in 20 participants. Currently enrolling.

Timeline
1 July 2025
Primary endpoint
30 June 2027
31 December 2027

Quick facts

Lead sponsorChinese PLA General Hospital
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment20
Start date1 July 2025
Primary completion30 June 2027
Estimated completion31 December 2027
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Chinese PLA General Hospital

Who can join

22 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this prospective, single-arm, open-label study is to assess the safety and efficacy of the staged, dual-target(VIM+PTT thalamotomy)to treat Patiensts with Parkinson Disease using transcranial magnetic resonance guided focused ultrasound system ExAblate 4000, InSightec Ltd.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07044973.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing